Direct brain infusion of glial cell line-derived neurotrophic factor in Parkinson disease

Research output: Contribution to journal/Conference contribution in journal/Contribution to newspaperJournal articleResearchpeer-review


  • Steven S. Gill, Frenchay Hospital
  • ,
  • Nikunj K. Patel, Frenchay Hospital
  • ,
  • Gary R. Hotton, Hammersmith Hospital
  • ,
  • Karen O'Sullivan, Frenchay Hospital
  • ,
  • Renée McCarter, Frenchay Hospital
  • ,
  • Martin Bunnage, Frenchay Hospital
  • ,
  • David J. Brooks
  • Clive N. Svendsen, University of Wisconsin-Madison
  • ,
  • Peter Heywood, Frenchay Hospital

Glial cell line-derived neurotrophic factor (GDNF) is a potent neurotrophic factor with restorative effects in a wide variety of rodent and primate models of Parkinson disease, but penetration into brain tissue from either the blood or the cerebro-spinal fluid is limited. Here we delivered GDNF directly into the putamen of five Parkinson patients in a phase 1 safety trial. One catheter needed to be repositioned and there were changes in the magnetic resonance images that disappeared after lowering the concentration of GDNF. After one year, there were no serious clinical side effects, a 39% improvement in the off-medication motor sub-score of the Unified Parkinson's Disease Rating Scale (UPDRS) and a 61% improvement in the activities of daily living sub-score. Medication-induced dyskinesias were reduced by 64% and were not observed off medication during chronic GDNF delivery. Positron emission tomography (PET) scans of [18F]dopamine uptake showed a significant 28% increase in putamen dopamine storage after 18 months, suggesting a direct effect of GDNF on dopamine function. This study warrants careful examination of GDNF as a treatment for Parkinson disease.

Original languageEnglish
JournalNature Medicine
Pages (from-to)589-595
Number of pages7
Publication statusPublished - 1 May 2003
Externally publishedYes

See relations at Aarhus University Citationformats

ID: 131254121